Affinity Investment Advisors LLC Has $1.45 Million Holdings in Pfizer Inc. (NYSE:PFE)

Affinity Investment Advisors LLC increased its holdings in shares of Pfizer Inc. (NYSE:PFE) by 25.5% during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 57,326 shares of the biopharmaceutical company’s stock after acquiring an additional 11,650 shares during the period. Pfizer comprises approximately 1.2% of Affinity Investment Advisors LLC’s holdings, making the stock its 24th largest holding. Affinity Investment Advisors LLC’s holdings in Pfizer were worth $1,453,000 at the end of the most recent quarter.

Other institutional investors have also recently bought and sold shares of the company. CacheTech Inc. lifted its stake in shares of Pfizer by 10.6% during the first quarter. CacheTech Inc. now owns 25,402 shares of the biopharmaceutical company’s stock valued at $644,000 after acquiring an additional 2,426 shares during the period. Algert Global LLC acquired a new position in shares of Pfizer during the 1st quarter worth about $2,646,000. Cascade Financial Partners LLC increased its stake in shares of Pfizer by 2.3% in the 1st quarter. Cascade Financial Partners LLC now owns 26,817 shares of the biopharmaceutical company’s stock valued at $680,000 after acquiring an additional 594 shares during the last quarter. Round Hill Asset Management raised its position in shares of Pfizer by 20.4% in the 1st quarter. Round Hill Asset Management now owns 183,270 shares of the biopharmaceutical company’s stock valued at $4,644,000 after acquiring an additional 31,108 shares during the period. Finally, Windward Capital Management Co. CA raised its position in shares of Pfizer by 0.7% in the 1st quarter. Windward Capital Management Co. CA now owns 77,531 shares of the biopharmaceutical company’s stock valued at $1,965,000 after acquiring an additional 524 shares during the period. Institutional investors own 68.36% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts have recently weighed in on PFE shares. Morgan Stanley lifted their price target on shares of Pfizer from $32.00 to $33.00 and gave the stock an “equal weight” rating in a research report on Wednesday, August 6th. Citigroup increased their price target on Pfizer from $25.00 to $26.00 and gave the stock a “neutral” rating in a report on Wednesday, August 6th. Jefferies Financial Group lifted their price objective on Pfizer from $32.00 to $33.00 and gave the company a “buy” rating in a report on Wednesday, May 21st. Berenberg Bank lowered their target price on Pfizer from $28.00 to $25.00 and set a “hold” rating for the company in a research note on Thursday, May 29th. Finally, The Goldman Sachs Group raised their target price on shares of Pfizer from $25.00 to $27.00 and gave the stock a “neutral” rating in a report on Wednesday, April 30th. One research analyst has rated the stock with a sell rating, eleven have given a hold rating, five have issued a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat, Pfizer currently has a consensus rating of “Hold” and a consensus price target of $28.12.

Pfizer Stock Up 0.2%

PFE stock opened at $25.16 on Friday. The company has a market cap of $143.05 billion, a price-to-earnings ratio of 13.38, a P/E/G ratio of 0.89 and a beta of 0.52. The company has a quick ratio of 0.85, a current ratio of 1.16 and a debt-to-equity ratio of 0.65. Pfizer Inc. has a twelve month low of $20.92 and a twelve month high of $30.43. The business has a 50 day moving average price of $24.60 and a two-hundred day moving average price of $24.44.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 EPS for the quarter, topping analysts’ consensus estimates of $0.58 by $0.20. Pfizer had a return on equity of 21.42% and a net margin of 16.84%. The business had revenue of $14.65 billion during the quarter, compared to analysts’ expectations of $13.43 billion. During the same quarter last year, the company posted $0.60 earnings per share. Pfizer’s quarterly revenue was up 10.3% on a year-over-year basis. Analysts anticipate that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, September 2nd. Investors of record on Friday, July 25th will be paid a $0.43 dividend. The ex-dividend date is Friday, July 25th. This represents a $1.72 annualized dividend and a yield of 6.8%. Pfizer’s payout ratio is 91.49%.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.